by David Wheatley MD (Twickenham, Middlesex) I have been concerned with the evaluation of psychotropic drugs in general practice over the past ten years, as head of the General Practitioner Research Group.
The constitution of this group has been described elsewhere (Wheatley 1963) ; but briefly the group consists of 400 general practitioners, situated in all parts of the British Isles, who are conducting clinical trials on new and established drugs. For the past eight years, the group has been in receipt of research grants from the National Institute of Mental Health, US Public Health Service, (Grant Nos. MY-4135 (CI), MH-0413-05, for research into the use of psychotropic drugs in general practice, and this has formed a major part of our work.
Our main object was to try and determine the most suitable drugs for the treatment of the type of case seen by the general practitioner, i.e. the milder forms of neurotic illness. The general practitioner is constantly bombarded with pharmaceutical literature extolling the virtues of each new psychotropic drug, and suggesting that it is the ideal compound for the treatment of the majority of psychiatric cases seen in general practice. However, very often the drug concerned is a major thymoleptic, developed for the treatment of psychotic illness, which has been advocated for neurosis in a reduced dose. Very often the compound carries with it dangers of serious side-effects, which are not acceptable in neurotic illness, unless the drug can be shown to 'Requests for reprints may be sent to 325 Staines Road, Twickenham have some striking advantage over simpler remedies.
Our programme of research has been: Phase 1, comparison of basic drugs to placebos; phase 2, comparison of new drugs to standard drugs; phase 3, predictors of response to treatment; phase 4, other indications for psychotropic drugs; phase 5, new ideas.
Placebo Response
The first phase of our work was undertaken over eight years ago, at a time when the new tranquillizers were very much in vogue, and specific antidepressant drugs were relatively untried. We first wished to determine the effects of two basic forms of treatment, namely sedation in anxiety and CNS stimulation in depression, as compared to placebo, and four trials were undertaken: phenobarbitone v. placebo in anxiety; dexamphetamine v. placebo in neurotic depression; amphetamine-barbiturate combination v. the individual components in mixed anxiety-depression; methylpentynol v. phenobarbitone.
To sum up, we found that although there was a very high placebo reaction (something like 50% of the total response), the effect of phenobarbitone in anxiety was greater (of the order of 75 %), differences which were statistically significant at the 1 % level. In the case of dexamphetamine v. placebo in depression, better results were recorded with the placebo, and in mixed anxiety-depression better results were recorded with phenobarbitone alone, results with amphetamine alone being very poor. We found no difference in response between methylpentynol and phenobarbitone and no difference in the incidence of drowsiness (General Practitioner Clinical Trials (GPCT> 1964 , Wheatley 1969a ). Quite apart from the greater response to phenobarbitone in anxiety, there was a very high relapse rate subsequently in the patients treated with placebo as compared to those treated with phenobarbitone. We therefore concluded that the use of a sedative drug in anxiety was certainly justified, since it would be impossible to predict which patients might respond to placebo; but that the amphetamines had no place in the treatment of these conditions in general practice.
Choice ofStandard Drugs
We were not very happy about the use of barbiturates, and so we decided to compare phenobarbitone to chlordiazepoxide (Librium), a much safer drug as regards accidental overdosage. In two comparative trials (GPCT 1965 , Wheatley 1966a we found the two drugs to be equally good in acute anxiety states, but chlordiazepoxide to be superior to phenobarbitone in chronic anxiety states. We therefore adopted chlordiazepoxide as our standard comparative drug for future trials in anxiety.
With regard to depression, we decided to use amitriptyline or imipramine as standard reference drugs, since other tricycic compounds did not appear to offer any advantages over these, and monoamine oxidase inhibitors are impracticable and potentially dangerous for use in general practice.
Results ofAnxiety Trials
We compared the following drugs against the standard drug, chlordiazepoxide: pericyazine (Neulactil), oxazepam (Serenid-D), haloperidol (Serenace), triclofos (Tricloryl), medazepam (Nobrium), oxypertine (Integrin) (GPCT 1967a (GPCT , 1968b (GPCT , 1969b (GPCT , 1971b ; pimozide (Orap). Fig I shows the results in three of these trials, evaluating pericyazine compared to amylobarbitone: and oxazepam and haloperidol compared to chlordiazepoxide. These trials were conducted over four weeks in each case, patients being treated with one or other drug throughout, double-blind, with randomized allocation to treatment groups. It is seen that there were only small differences between the degrees of improvement in any of these trials, and none of the differences shown is statistically significant. The results in the subsequent trials on the other drugs mentioned were all of the same order. These results are typical of those to be expected in the drug treatment of anxiety, showing a relatively low (20 %) response in the first week, with gradual improvement over the next week or two, and an end-result of about 60% at 4 weeks (Wheatley 1968) . It was concluded that none of the drugs tested proved better than chlordiazepoxide, although in the case of medazepam results at 4 weeks were marginally better (P<005). However, it is doubtful whether this has any clinical significance, since medazepam was no more rapid in action than chlordiazepoxide.
Results in Neurotic Depression
We have compared the following drugs to either amitriptyline or imipramine: mebanazine (Actomol) (Wheatley 1965) ; trimipramine (Surmontil), protriptyline (Concordin), perphenazineamitriptyline (Triptafen), perphenazine (Fentazin), chlordiazepoxide-amitriptyline (Limbitrol), meprobamate-benactyzine (Idemin), oxypertine (Integrin) (General Practitioner Clinical Trials 1967b , 1968a , 1971c , Wheatley 1970a ); long-acting amitriptyline (Lentizol) (GPCT 1972a); UK 3557 (not marketed).
The results were of a similar order to those recorded in anxiety, showing a fairly small response in the first week, with gradual improvement in the second and third and maximum response by the fourth week. Once again, there were no differences in response between any of the individual drugs.
Antidepressant Effect due to Sedation ? It has been suggested that the effect of so-called antidepressant drugs is merely due to their sedative effect (Hare et al. 1962 , Hare et al. 1964 ). Therefore we compared imipramine with a purely sedative drug, phenobarbitone, in chronic cases of neurotic depression, over a period of eight weeks (Wheatley 1969b) . We found that there were no statistically significant differences in response between the two drugs except at the end of two weeks, when response was better to phenobarbitone than to imipramine (P<0 05). Subsequently we have compared perphenazine and chlordiazepoxide to amitriptyline and found similar effects from the two tranquillizing drugs (GPCT 1971a) , and also thioridazine to amitriptyline (GPCT 1972b), with similar results. Therefore, we concluded that in many cases of neurotic depression a tranquilizer may be just as beneficial as an antidepressant. (However, endogenous depression represents an entirely Section ofGeneralPractice different problem, and antidepressant drugs are necessary in such cases) (Hordem & Wheatley 1972) .
Predictors ofResponse
Since it is impossible to predict which patients will respond to placebo, it is necessary to exhibit an active drug to all. If we could detect cases where a good effect might be expected, then drugs could be used in a much more efficient and economical manner. Therefore, in all our trials we have recorded a number of items of patient data, and then analysed the results separately in relation to these various subgroups of patients. Of course, in any one trial, usually involving up to 100 cases, some of these subgroups can be very small (the very young or the very old, for instance) and so we have combined the results of a large number of trials, so that we can compare these subgroups for overall type of drug response (i.e. response to all tranquillizers), or response to specific drugs (i.e. to chlordiazepoxide, used as the standard in a number of trials).
We have investigated the following factors in this manner: sex and age; doctors' and patients' attitudes; marital status; social class; frequency of previous attacks; precipitating causes; duration; previous therapy; religion; educational level; number of children; number of persons living with the patient; place and circumstances of birth; work status.
We found that in anxiety the response to tranquillizers was considerably influenced by both doctors' and patients' attitudes, there being significant differences (P<0-01) in relation to the three categories ofattitude (optimistic, indifferent, pessimistic), these differences being more marked in the case of the doctors' than of the patients' attitudes. On the other hand, in neurotic depression, no such differences were demonstrated with antidepressant drugs (Wheatley 1966b (Wheatley , 1967 .
A number of other factors also influence the response to treatment (Wheatley 1970b ): Marital status: Single patients respond better than married, in anxiety but not in depression. Frequency ofprevious attacks: Response is better with no previous attacks (or the fewer the previous attacks) in anxiety (not recorded in depression). Duration: Response is better when duration is under one year than when it is over one year, in both anxiety and depression. Previous therapy: Response is better when there has been no previous therapy, or when it has been previously successful, in depression (not yet analysed in anxiety). Education: Response is better the higher the patient's educational level, in depression (not yet analysed in anxiety).
Religion: Response is better in Roman Catholics than in Jews, in depression (not yet analysed in anxiety).
These differences all refer to statistically significant levels of 5%. The total number of cases recorded in these studies is over 1,500.
None of the other factors considered was shown to influence the response to treatment.
We are currently investigating the effects of menstrual status in women, and also accumulating more information on educational level and religion.
Comparatively large numbers of cases were required before differences became significant (in anxiety no factor emerged until just over 250 cases had been analysed); so from a practical point of view, we cannot conclude that any knowledge of predictors is of help in defining the patients most likely to respond to psychotropic drugs.
Other Indications
We have considered the use of psychotropic drugs for nonpsychiatric indications, and have undertaken trials on the following. Tricyclic antidepressants in enuresis: We have conducted two trials, of imipraniine and trimipramine, in children and found tricyclic antidepressant therapy to be very effective (GPCT 1969c) .
Opipramol (Insidon) in the menopause: We have compared opipramol to placebo, to phenobarbitone, and to stilboestrol (GPCT 1972c) . Results for opipramol were better than those for placebo and for phenobarbitone, and equal to those for stilboestrol. We concluded that there is a place for psychotropic drugs in the control of menopausal symptoms.
Tranquillizer-anticholinergic combination in peptic ulceration: We have compared a combination of opipramol and propantheline (Pro-Banthine) to their use singly. We found that the combination had no advantages and produced a high level of side-effects; used singly, equally good results were recorded with the tranquillizer as with the anticholinergic (GPCT 1971d) . We concluded that there may be a use for tranquilizers in peptic ulceration.
There are many other indications for psychotropic drugs in general practice, and this may be a very important field for their use; in the USA the majority of all psychotropic drugs administered are prescribed by general practitioners (Balter & Levine 1969).
New Ideas
We have turned our attention to nonpsychotropic drugs that might nevertheless have an action in psychiatric illness. Propanolol in anxiety: Following the report by Granville-Grossman & Turner (1966) of an anxiolytic effect of this beta-adrenergic blocking drug in anxiety, as compared to placebo, we undertook a trial to compare propranolol to chlordiazepoxide. We found similar results from the two drugs, but in depressive mood and sleep disturbance chlordiazepoxide was superior (Wheatley 1969c) . We are now considering further studies with some of the new beta-adrenergic blocking drugs, such as practolol. Potentiation of tricyclics by thyroid hormone:
Following the work of Prange et al. (1968 Prange et al. ( , 1969 , we have completed a study comparing the antidepressant effect of two doses of triiodothyronine added to amitriptyline, as against amitriptyline alone, and have confirmed their findings (Wheatley 1972) ; results were assessed on the Hamilton rating scales (Fig 2) and the NIMH self-rating scales. On both scales the differences in response were statistically significant at 14 days (P<0 05), and on the self-rating scales also at 10 days. There were significant differences in relation to the dose of triiodothyronine, results being better with the higher dose.
We are at present planning a trial of perphenazine-amitriptyline v. imipramine in depression, following the results of Coppen et al. (1967) .
Conclusions
(1) There is a large placebo response in both anxiety neurosis and neurotic depression, but there is a significantly greater response by a greater number of patients when a specific psychotropic drug is used.
(2) None of the newer drugs that we have investigated has proved to be significantly better than the two standard drugs, namely: chlordiazepoxide in anxiety, and amitriptyline in depression.
However, in many cases of neurotic depression, a tranquillizer may give as good results as an antidepressant, and may produce a more rapid response.
(3) Although response to psychotropic drugs in neurotic illness is significantly better in certain groups of patients, this is probably of little clinical significance in predicting response in practice. However, the more optimistic the attitude of doctor and patient, the more likely is an effective response to treatment.
(4) There are many other useful indications for psychotropic drugs in general practice. In conditions such as menopausal symptoms and peptic ulceration there may be a large psychiatric element that requires treatment with psychotropic drugs, rather than drugs specifically designed for the condition. (5) The main deficiency in treating neurotic illness in general practice with psychotropic drugs is the slow onset of action of both tranquillizers and antidepressants. A much more rapid effect is required within the first week, and it may be necessary to consider using nonpsychotropic drugs, such as triiodothyronine for this purpose.
